Standard BioTools Withdraws 2026 Outlook Ahead of Treeline Merger

• Standard BioTools reported a Q2 2026 loss of -$0.07 per share, an improvement from -$0.09 in the prior year period, despite a 7.6% drop in revenue to $20.1 million.
• The company withdrew its full-year 2026 revenue outlook to focus on its pending merger with Treeline Biosciences and the divestiture of its Mass Cytometry business.
• Adjusted EBITDA losses contracted significantly to $2.5 million due to aggressive cost-cutting, even as one-time transaction charges widened the net loss from continuing operations.
• Institutional investors have increased their stakes, with Millennium Management LLC lifting holdings by 133%, while analyst consensus remains cautious with a Hold rating.

Standard BioTools Inc. (LAB) reported a second-quarter loss of $26.758 million, or -$0.07 per share, marking an improvement from the -$33.459 million loss, or -$0.09 per share, recorded in the same period last year . Revenue for the quarter fell 7.6% year-over-year to $20.104 million, down from $21.762 million previously . In conjunction with the earnings release, Standard BioTools announced it is withdrawing its full-year 2026 revenue outlook . This decision comes as the company navigates a pending merger with Treeline Biosciences . The withdrawal of guidance reflects the transitional nature of the business as it prepares for this strategic combination, which is expected to reshape its operational profile .

While top-line revenue declined, Standard BioTools saw significant improvements in gross margin and adjusted EBITDA due to strict cost discipline and restructuring efforts . The company highlighted that its strategic transactions are proceeding as planned . The merger with Treeline Biosciences is moving forward, alongside the divestiture of the Mass Cytometry business . These actions indicate a pivot towards a more streamlined cost structure, even as the company navigates revenue headwinds and prepares for the integration of the Treeline acquisition .

Despite the top-line contraction, the company demonstrated improved operational efficiency . Gross margins and adjusted EBITDA saw significant improvement, driven by disciplined cost management and ongoing restructuring initiatives . The company emphasized strong liquidity, citing $541.1 million in cash and investments as of June 30, 2026 . This robust cash position provides a buffer as the company transitions its business model away from legacy instrument sales toward a focused biopharma pipeline focus.

While the net loss from continuing operations widened to $21.5 million due to one-time transaction charges, the operating loss improved slightly . Adjusted EBITDA loss contracted significantly to $2.5 million, reflecting the impact of aggressive cost-cutting and restructuring measures . The company emphasized its strong liquidity position, citing $541.1 million in cash and investments as of June 30, 2026 .

Strategically, Standard BioTools confirmed that its merger with Treeline Biosciences is on track for a shareholder vote and an expected close before year-end . The merger is viewed as the primary path to maximize shareholder value by providing exposure to Treeline’s catalyst-rich therapeutic pipeline . CEO Michael Egholm stated that the company remains on track to close the merger before year-end 2026 . This progress is supported by the previously filed registration statement on Form S-4 and an agreement to divest the Mass Cytometry business .

The planned sale of its Mass Cytometry unit is proceeding, ensuring continuity for CyTOF and Hyperion product lines while allowing Standard BioTools to focus resources on its merger with Treeline Biosciences . The merger, originally announced in June 2026, involves the combined entity operating under the name Treeline Biosciences . The transaction is backed by a strong financial position, with over $900 million expected at closing .

In light of the pending transaction and the planned sale of its Mass Cytometry unit, Standard BioTools withdrew its full-year 2026 revenue outlook . This withdrawal underscores a strategic shift aimed at reshaping the business profile and value proposition for shareholders as the company transitions toward its new capital structure and operational focus following the Treeline merger .

Analyst sentiment remains cautious, with the most recent rating on LAB stock being a Hold and $1.35 price target. Technical indicators show the stock trading below all major moving averages . While corporate actions such as the merger and asset sales provide strategic support, these are tempered by renewed Nasdaq bid-price compliance risks and weakening financial performance metrics, including sharply declining trailing-twelve-month revenue and persistent negative free cash flow .

Institutional ownership stands at 53.74%, with significant activity reported during the fourth quarter. State Street Corp now owns 6,482,766 shares worth $8,298,000 after purchasing an additional 80,117 shares . Millennium Management LLC increased its holdings by 133.0%, now owning 3,387,428 shares valued at $4,336,000 after buying an additional 1,933,853 shares . ARK Investment Management LLC also lifted its position by 1.5%, holding 3,066,665 shares valued at $3,925,000 .

On the analyst front, Weiss Ratings upgraded Standard BioTools from a 'sell (d)' to a 'sell (d+)' rating on July 21st . Current consensus data from MarketBeat.com indicates an average 'Reduce' rating, with two analysts holding the stock and one issuing a sell rating . The consensus price target is set at $1.35 .

Standard BioTools, formerly known as Fluidigm Corporation, operates in the life sciences tools industry, providing high-parameter single-cell and spatial biology solutions . Its platforms integrate microfluidics, mass cytometry, sequencing, and imaging to help researchers probe cellular heterogeneity and molecular interactions . Flagship products include mass cytometry systems like the Helios and Hyperion Imaging System, as well as Chromium-style single-cell genomic tools for high-throughput gene expression profiling .

What does the withdrawal of guidance signal for investors? The withdrawal of the full-year 2026 revenue outlook signals a significant shift in the company's business profile and value proposition as it navigates the transition . This move underscores the strategic transition underway as the company prepares for corporate restructuring and potential asset divestitures. The company is moving away from its legacy instrument business toward a focused biopharma pipeline .

How is the merger with Treeline Biosciences expected to impact the company? The merger with Treeline Biosciences is expected to reshape the operational profile of the combined entity, which will operate under the name Treeline Biosciences . The transaction provides exposure to Treeline’s deep clinical-stage pipeline of small molecule inhibitors and protein degraders . Planned data updates for key assets TLN-121 and TLN-372 are expected in 2027 . This strategic combination aims to maximize shareholder value by leveraging Treeline’s catalyst-rich therapeutic pipeline .